IP Library Granted Patent US 10,195,435
Granted Patent B2
US 10,195,435 · App. 15/348,097 · Granted Feb 5, 2019

Extracranial implantable devices, systems and methods for the treatment of neuropsychiatric disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,195,435
App. No.
15/348,097
Granted
Feb 5, 2019
Kind
B2
Abstract

The present disclosure relates to methods, devices, and systems used for the treatment of mood, anxiety, cognitive, and behavioral disorders (collectively, neuropsychiatric disorders) via stimulation of the superficial elements of the trigeminal nerve (“TNS”). More specifically, minimally invasive systems, devices and methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, nasal and mentalis nerves (also referred to collectively as the superficial trigeminal nerve) are disclosed herein.

Claims (24)

1. A method for treating a neuropsychiatric disorder by trigeminal nerve stimulation, comprising:

implanting a subcutaneous electrode assembly below an epidermis and above a pericranium of a patient to place a first electrode contact laterally to a first ophthalmic nerve on one side of the patient's forehead and to place a second electrode contact medially to the first ophthalmic nerve; and

applying electrical signals to the subcutaneous electrode assembly at specified operational parameters to treat the neuropsychiatric disorder.

2. The method of claim 1 , wherein the implanting comprises implanting the subcutaneous electrode assembly below the epidermis and above the pericranium of the patient to place a third electrode contact laterally to a second ophthalmic nerve on an opposing side of the patient's forehead and to place a fourth electrode contact medially to the second ophthalmic nerve.

3. The method of claim 1 , wherein the first ophthalmic nerve comprises the supraorbital nerve, the supratrochlear nerve, or both.

4. The method of claim 1 , wherein the electrical signals are applied to minimize current penetration into the patient's brain such that a charge density at a surface of the patient's brain does not exceed 20 μC/cm 2 .

5. The method of claim 1 , wherein the applying comprises applying electrical signals at a frequency between approximately 20 and 300 Hz, at a current of 0.1 to 3 mA, and at a pulse duration of less than or equal to 500 μs.

6. The method of claim 1 , wherein the applying comprises applying electrical signals at a frequency between approximately 20 and 300 Hz, at a pulse duration between approximately 50 and 500 μs, at an output current density of not greater than approximately 25 mA/cm 2 , and a charge density of not greater than approximately 10 μC/cm 2 at the patient's cerebral cortex.

7. The method of claim 1 , wherein the neuropsychiatric disorder is selected from the group consisting of a mood disorder, a cognitive disorder, a behavioral disorder, an anxiety disorder, or a combination thereof.

8. The method of claim 1 , wherein the neuropsychiatric disorder is a disorder affecting attention, cognition, behavior, or a combination thereof.

9. The method of claim 1 , wherein the neuropsychiatric disorder is depression or major depressive disorder.

10. The method of claim 1 , wherein the neuropsychiatric disorder is post-traumatic stress disorder.

11. A method for treating a neuropsychiatric disorder by trigeminal nerve stimulation, comprising:

implanting a subcutaneous electrode assembly below an epidermis and above a pericranium of a patient to place a first electrode contact laterally to a first supraorbital nerve on one side of the patient's forehead and to place a second electrode contact medially to the first supraorbital nerve; and

applying electrical signals to the subcutaneous electrode assembly at specified operational parameters to treat the neuropsychiatric disorder.

12. The method of claim 11 , wherein the implanting comprises implanting the subcutaneous electrode assembly below the epidermis and above the pericranium of the patient to place a third electrode contact laterally to a second supraorbital nerve on an opposing side of the patient's forehead and to place a fourth electrode contact medially to the second supraorbital nerve.

13. The method of claim 11 , wherein the implanting comprises implanting the subcutaneous electrode assembly below the epidermis and above the pericranium of the patient to place a third electrode contact laterally to a first supratrochlear nerve on the one side of the patient's forehead and to place a fourth electrode contact medially to the first supratrochlear nerve.

14. The method of claim 13 , wherein the implanting comprises implanting the subcutaneous electrode assembly below the epidermis and above the pericranium of the patient to place a fifth electrode contact laterally to a second supraorbital nerve on an opposing side of the patient's forehead, a sixth electrode contact medially to the second supraorbital nerve, a seventh electrode contact laterally to a second supratrochlear nerve on the opposing side of the patient's forehead, and an eighth electrode contact medially to the second supratrochlear nerve.

15. The method of claim 11 , wherein the electrical signals are applied to minimize current penetration into the patient's brain such that a charge density at a surface of the patient's brain does not exceed 20 μC/cm 2 .

16. The method of claim 11 , wherein the applying comprises applying electrical signals at a frequency between approximately 20 and 300 Hz, at a current between approximately 0.1 and 3 mA, at a pulse duration between approximately 50 and 500 μs, at an output current density of not greater than approximately 25 mA/cm 2 , at a charge density of not greater than approximately 10 μC/cm 2 at the patient's cerebral cortex, or a combination thereof.

17. The method of claim 11 , wherein the neuropsychiatric disorder is selected from the group consisting of a mood disorder, a cognitive disorder, a behavioral disorder, an anxiety disorder, or a combination thereof.

18. The method of claim 11 , wherein the neuropsychiatric disorder is a disorder affecting attention, cognition, behavior, or a combination thereof.

19. The method of claim 11 , wherein the neuropsychiatric disorder is depression or major depressive disorder.

20. The method of claim 11 , wherein the neuropsychiatric disorder is post-traumatic stress disorder.

Assignments (1)
LIEN Recorded Mar 20, 2019
From: NEUROSIGMA, INC.
To: DE SALLES, ANTONIO A.F.; GORGULHO, ALESSANDRA
Reel/Frame 048649/0380 →
Cited By (1)
US 12,465,776